Cannabis medicinal: ciência, inovação e avanços clínicos. Revisão integrativa da literatura

Autores

DOI:

https://doi.org/10.69940/sld.20260406

Palavras-chave:

Cannabis medicinal, THC e CBD, uso medicinal

Resumo

Introdução: A Cannabis sativa é uma planta da família Cannabaceae com ampla utilização medicinal. A sua composição inclui mais de 100 compostos ativos, destacando-se o tetrahidrocanabinol (THC), que provoca efeitos psicoativos, e o canabidiol (CBD), que tem propriedades terapêuticas sem alterar a cognição. Historicamente, a cannabis tem sido um remédio natural em diversas culturas, mas a sua proibição no século XX limitou a investigação científica.  Objetivo: Este artigo tem como objetivo revisar os avanços recentes na investigação sobre a cannabis medicinal, com foco na sua eficácia clínica em diversas patologias e nas implicações éticas e regulatórias do seu uso. Materiais e Métodos: Esta revisão baseia-se em pesquisas em bases de dados como Medline, Lilacs, SciELO e Google Académico, analisando o impacto da cannabis em doenças neurológicas. Discussão: As evidências sugerem que pode ser benéfico no tratamento da dor crónica, espasticidade na esclerose múltipla e sintomas de distúrbios como ansiedade e transtorno de stress pós-traumático (TEPT). No entanto, o seu uso na medicina enfrenta desafios, como a falta de padronização na produção e dosagem, o que complica a obtenção de resultados consistentes. A variabilidade na resposta individual, as barreiras regulatórias e o estigma social também dificultam a sua aceitação. Apesar desses desafios, as evidências crescentes sobre os seus benefícios levaram a uma reavaliação do seu potencial terapêutico e a uma mudança na sua regulamentação em alguns países, permitindo que mais pacientes tenham acesso a tratamentos com cannabis.

Downloads

Os dados de download ainda não estão disponíveis.

Referências

Monteiro de Sousa L, Vieira Baião MK. Maconha medicinal (Cannabis sativa): usos e perspectivas clínicas [Internet]. Goiânia, GO, Brasil: Pontifícia Universidade Católica de Goiás, Escola de Ciências Médicas e da Vida, Curso de Graduação em Farmácia; 2021 [citado 2025 abr 2]. Disponible en: https://repositorio.pucgoias.edu.br/jspui/bitstream/123456789/3118/1/TCC%20-

%20Larissa%20e%20Maria%20Karulyna.pdf

Alonso Esteban JI, Sánchez Mata MC, Torija Isasa E. Historical evolution of taxonomic classification of hemp. Boletín de la Real Sociedad Española de Historia Natural 2021;115:147-154. doi: 10.29077/bol.115.e04.alonso.

Gómez Velásquez S, Amaya Heredia ÁM, Bedoya Moncada S, Patiño González JE, Martínez Ramírez JA. Recreational cannabis: profile of cannabinoids present in marijuana samples supplied by the consuming population. Salud Colect [Internet]. 2023 [citado 2025 abr 2];19:e4385. Disponible en: https://www.scielosp.org/article/scol/2023.v19/e4385/es

Pérez Martínez J. Aspectos prácticos de la elección del producto y la titulación con cannabis medicinal para el dolor crónico. Rev Soc Esp Dolor [Internet]. 2022 [citado 2025 abr 2];29:43–51. Disponible en: https://scielo.isciii.es/pdf/dolor/v29s1/1134-8046-dolor-29-s1-43.pdf

Al-Khazaleh AK, Zhou X, Bhuyan DJ, Münch GW, Al-Dalabeeh EA, Jaye K, Chang D. The neurotherapeutic arsenal in cannabis sativa: Insights into anti-neuroinflammatory and neuroprotective activity and potential entourage effects. Molecules. 2024;29(2). doi: http://dx.doi.org/10.3390/molecules29020410

D’Souza DC, Castle D, Murray SR. Pharmacology of cannabis and the endocannabinoid system. En: Marijuana and Madness. Cambridge, England: Cambridge University Press; 2023. p. 1–30.

Britch SC, Babalonis S, Walsh SL. Cannabidiol: pharmacology and therapeutic targets. Psychopharmacology (Berl). 2021;238(1):9–28. doi: http://dx.doi.org/10.1007/s00213-020-05712-8

Dos Santos Sampaio MF, de Paiva YB, Sampaio TB, Pereira MG, Coimbra NC. Therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and Parkinson’s disease and in comorbidity with psychiatric disorders. Basic Clin Pharmacol Toxicol. 2024;134(5):574–601. doi: http://dx.doi.org/10.1111/bcpt.13997

Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes C, Lang S, Misso K, Ryder S, Schmidlkofer S, Westwood M, Kleijnen J. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456-2473. doi. http://dx.doi.org/10.1001/jama.2015.6358

Hoch E, Volkow ND, Friemel CM, Lorenzetti V, Freeman TP, Hall W. Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits. Eur Arch Psychiatry Clin Neurosci. 2025;275(2):281-292. doi: https://doi.org/10.1007/s00406-024-01880-2

Stains EL, Kennalley AL, Tian M, Boehnke KF, Kraus CK, Piper BJ. Medical cannabis in the United States: comparing 2017 and 2024 state qualifying conditions to the 2017 National Academies of Sciences report. Mayo Clin Proc Innov Qual Outcomes. 2025;9(2):100590. doi: http://dx.doi.org/10.1016/j.mayocpiqo.2025.100590

Cáceres Guido P. Cannabis medicinal: más allá del mito, solo otra droga (vegetal). Salud Colect. 2022;18:e4078. doi: http://dx.doi.org/10.18294/sc.2022.4078

Yndart Arias A, Vadell K, Vashist A, Kolishetti N, Lakshmana MK, Nair M, et al. Cannabidiol, a plant-derived compound, is an emerging strategy for treating cognitive impairments: comprehensive review of randomized trials. Front Pharmacol. 2024;15:1403147. doi: http://dx.doi.org/10.3389/fphar.2024.1403147

Coelho C de F, Vieira RP, Araújo-Junior OS, Lopes-Martins PSL, Dos Santos LG, Dias LD, et al. The impact of cannabidiol treatment on anxiety disorders: A systematic review of randomized controlled clinical trials. Life (Basel). 2024;14(11):1373. doi: http://dx.doi.org/10.3390/life14111373

Grimison P, Mersiades A, Kirby A, Tognela A, Olver I, Morton RL, et al. Oral cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: final results of a randomized, placebo-controlled, phase II/III trial. J Clin Oncol. 2024;42(34):4040–50. doi: http://dx.doi.org/10.1200/JCO.23.01836

Putri NPA, Sarasmita MA, Sari PMNA, Wati DK, Wirasuta IMAGW. Therapeutic potential of cannabidiol (CBD) for neurological disorders: A systematic review of anti-inflammatory and neuroprotective effects. Afr J B Res. 2024;27(4):10630-10650. doi: http://dx.doi.org/10.53555/ajbr.v27i4s.5040

Yenilmez F, Fründt O, Hidding U, Buhmann C. Cannabis in Parkinson’s disease: the patients’ view. J Parkinsons Dis. 2021;11(1):309-321. doi: http://dx.doi.org/10.3233/JPD-202260

Strand NH, Maloney J, Kraus M, Wie C, Turkiewicz M, Gomez DA, et al. Cannabis for the treatment of fibromyalgia: a systematic review. Biomedicines. 2023;11(6):1621. doi: http://dx.doi.org/10.3390/biomedicines11061621

Herrera F. Estudio: dolor oncológico, cuidados paliativos y cannabis con fines medicinales [Internet]. Fundación Daya. 2023 [citado 2025 abr 2]. Disponible en: https://fundaciondaya.org/estudio-dolor-oncologico-cuidados-paliativos-y-cannabis-con-fines-medicinales/

Dos Santos RW, Viera de Cáceres SB. El tratamiento del alzheimer precoz – una mirada humanizada, reporte de caso clínico. UNIDA Sld. 2025;4(1):33-41. doi: http://dx.doi.org/10.69940/sld.20250407

Herrero Trujillano M. Cannabis medicinal y cáncer: beneficios en dolor oncológico y otros síntomas relacionados. Rev Soc Esp Dolor. 2022;29:14-19. doi: https://dx.doi.org/10.20986/resed.2022.4026/2022

St. Paul Minnesota. Estudio muestra que pacientes encuentran alivio del dolor con cannabis medicinal. El Minnesota de Hoy [Internet]. 2025 [citado 2025 abr 2]. Disponible en: https://www.elminnesotadehoy.com/estudio-muestra-que-pacientes-encuentran-alivio-del-dolor-con-cannabis-medicinal/

Gómez-García DM, García-Perdomo HA. Cannabis medicinal: puntos críticos para su uso clínico. Biomedica. 2022;42(3):450-459. doi: http://dx.doi.org/10.7705/biomedica.6468

Kaufmann CN, Malhotra A, Yang KH, Han BH, Nafsu R, Lifset ET, et al. Cannabis use for sleep disturbance among older patients in a geriatrics clinic. Int J Aging Hum Dev. 2023;97(1):3–17. doi: http://dx.doi.org/10.1177/00914150221128971

Sexton M, Garcia JM, Jatoi A, Clark CS, Wallace MS. The management of cancer symptoms and treatment-induced side effects with cannabis or cannabinoids. J Natl Cancer Inst Monogr. 2021;58:86-98. doi: http://dx.doi.org/10.1093/jncimonographs/lgab011

NORML. Analysis: Cannabis products provide sustained improvements in sleep quality for patients with insomnia [Internet]. NORML. 2024 [citado 2025 abr 2]. Disponible en: https://norml.org/news/2024/02/15/analysis-cannabis-products-provide-sustained-improvements-in-sleep-quality.

Makhakhe L. Topical cannabidiol (CBD) in skin pathology - a comprehensive review and prospects for new therapeutic opportunities. S Afr Fam Pract. 2022;64(1):a5493. doi: http://dx.doi.org/10.4102/safp.v64i1.5493

García de Palau M. Características de las vías de administración de cannabis - actualización [Internet]. Fundacion-canna.es. [citado 2025 abr 2]. Disponible en: https://www.fundacion-canna.es/caracteristicas-de-las-vias-de-administracion-de-cannabis-actualizacion

Monfort A, Ferreira E, Leclair G, Lodygensky GA. Pharmacokinetics of cannabis and its derivatives in animals and humans during pregnancy and breastfeeding. Front Pharmacol. 2022;13:919630. doi: http://dx.doi.org/10.3389/fphar.2022.919630

Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol. 2018;84(11):2477-2482. doi: http://dx.doi.org/10.1111/bcp.13710

Volkow ND, Baler RD, Compton WM, Weiss SRB. Adverse health effects of marijuana use. N Engl J Med. 2014;370(23):2219-2227. doi: http://dx.doi.org/10.1056/NEJMra1402309

Kochen S. Medical cannabis. Salud Colect. 2022;18:e3991. doi: https://doi.org/10.18294/sc.2022.3991.

Prospéro García OE, Ruiz Contreras AE, Cortés Morelos J, Herrera Solís A, Méndez Díaz M. Marihuana: legalización y atención médica. Rev Fac Med Univ Nac Auton Mex. 2019;62(6):6–23. doi: https://doi.org/10.22201/fm.24484865e.2019.62.6.02

Díaz MC. Un recorrido panorámico por iniciativas educativas sobre Cannabis en Argentina. Mediações [Internet]. 2023 [citado 2025 abr 2];28(3):1-18. Disponible en: https://www.scielo.br/j/mediacoes/a/8yG5cLFhGfYFQMgr7Km7vrs.

Martín-Sánchez E, Furukawa TA, Taylor J, Martin JLR. Systematic review and meta-analysis of cannabis treatment for chronic pain. Pain Med. 2009;10(8):1353-1368. doi: http://dx.doi.org/10.1111/j.1526-4637.2009.00703.x

Longoria V, Parcel H, Toma B, Minhas A, Zeine R. Neurological benefits, clinical challenges, and neuropathologic promise of medical marijuana: A systematic review of cannabinoid effects in multiple sclerosis and experimental models of demyelination. Biomedicines. 2022;10(3):539. doi: http://dx.doi.org/10.3390/biomedicines10030539

Koo CM, Kim SH, Lee JS, Park BJ, Lee HK, Kim HD, et al. Cannabidiol for treating Lennox-Gastaut syndrome and Dravet syndrome in Korea. J Korean Med Sci. 2020;35(50):e427. doi: http://dx.doi.org/10.3346/jkms.2020.35.e427

García-Gutiérrez MS, Navarrete F, Gasparyan A, Austrich-Olivares A, Sala F, Manzanares J. Cannabidiol: a potential new alternative for the treatment of anxiety, depression, and psychotic disorders. Biomolecules. 2020;10(11):1575. doi: http://dx.doi.org/10.3390/biom10111575

Herrera F. El uso de cannabis medicinal para el tratamiento de la fibromialgia y otros síntomas asociados: una revisión de la evidencia científica [Internet]. Fundación Daya. 2025 [citado 2025 abr 2]. Disponible en: https://fundaciondaya.org/el-uso-de-cannabis-medicinal-para-el-tratamiento-de-la-fibromialgia-y-otros-sintomas-asociados-una-revision-de-la-evidencia-cientifica/

Filippini G, Minozzi S, Borrelli F, Cinquini M, Dwan K. Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. Cochrane Database Syst Rev. 2022;5:CD013444. doi: http://dx.doi.org/10.1002/14651858.CD013444.pub2

Regueras E, Torres LM, Velazquez I. Cannabinoides y dolor (parte I). Multidisciplinary Pain Journal. 2023;142-162. doi: http://dx.doi.org/10.20986/mpj.2023.1052/2023

Cannava. Guía de manejo clínico de cannabis medicinal [Internet]. Gobierno de Jujuy Ministerio de Salud; 2021 [citado 2025 abr 2]; Disponible en: https://cannava.com.ar/archivos/GuiaManejoClinicoCannabisMedicinal2023.pdf

FDA US Food & Drug Administration. FDA Regulation of Cannabis and Cannabis-derived products, including cannabidiol (CBD) [Internet]. US Food and Drug Administration; 2024 [citado 2025 abr 2]. Disponible en: https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd

CBC News. Cannabis in Canada – here´s what you need to know [Internet]. 2018 Oct 17 [citado 2025 abr 2]. Disponible en: https://www.cbc.ca/news/canada/marijuana-faq-legalization-need-to-know-1.4862207

Cioffi A, Cecannecchia C, David MC, Cipolloni L, Santurro A. Cannabis regulatory system in European Union countries, forensic concept of “doping dose” and medico-legal implications. Med Leg J. 2023;91(3):128-135. doi: http://dx.doi.org/10.1177/00258172231166272

Department of Health. Victoria, Australia. Frequently asked questions about medicinal cannabis [Internet]. State Government of Victoria, Australia. [citado 2025 abr 2]. Disponible en: https://www.health.vic.gov.au/drugs-and-poisons/frequently-asked-questions-about-medicinal-cannabis

Our Cannabis Sector Experts. Regulación del cannabis medicinal en América Latina [Internet]. Biz Latin Hub. 2019 [citado 2025 abr 2]. Disponible en: https://www.bizlatinhub.com/es/entender-el-sector-del-cannabis-

latinoamericano/

Biblioteca y Archivo Central del Congreso Nacional. Ley No 6007 / Crea el Programa Nacional para el Estudio y la Investigación Médica y científica del uso medicinal de la planta de Cannabis y sus derivados [Internet]. Biblioteca y Archivo Central del Congreso Nacional. 2021 [citado 2025 abr 2]. Disponible en: https://www.bacn.gov.py/leyes-paraguayas/9911/ley-n-6007-crea-el-programa-nacional-para-el-estudio-y-la-investigacion-medica-y-cientifica-del-uso-medicinal-de-la-planta-de-cannabis-y-sus-derivados.

Dirección Nacional de Vigilancia Sanitaria (DNVS). Resolución N° 65/2021. Por la cual se establece los requisitos para el registro sanitario de productos derivados del cannabis con cannabidiol (CBD) como principio activo [Internet]. Ministerio de Salud Pública y Bienestar Social de Paraguay; 2021 [citado 2025 abr 2]. Disponible en: https://dinavisa.gov.py/wp-content/uploads/2023/09/Resolucion-DNVS-N-65-2021.pdf

Hossain MK, Chae HJ. Medical cannabis: from research breakthroughs to shifting public perceptions and ensuring safe use. Integr Med Res. 2024;13(4):101094. doi: http://dx.doi.org/10.1016/j.imr.2024.101094

Kitdumrongthum S, Trachootham D. An individuality of response to cannabinoids: Challenges in safety and efficacy of cannabis products. Molecules. 2023;28(6):2791. doi: http://dx.doi.org/10.3390/molecules28062791

Alexander SP. Barriers to the wider adoption of medicinal Cannabis. Br J Pain. 2020;14(2):122-132. doi: http://dx.doi.org/10.1177/20494637209228

Publicado

2026-01-26

Edição

Seção

Artículos de revisión

Como Citar

1.
Dos Santos RW, Paoli Ruiz SC. Cannabis medicinal: ciência, inovação e avanços clínicos. Revisão integrativa da literatura. UNIDA Sld. [Internet]. 26 de janeiro de 2026 [citado 9 de novembro de 2026];5(1):24-36. Disponível em: https://revistacientifica.unida.edu.py/publicaciones/index.php/unidasld/article/view/316